TIAA CREF Investment Management LLC lowered its position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 2.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,500 shares of the company’s stock after selling 414 shares during the period. TIAA CREF Investment Management LLC owned about 0.07% of Reata Pharmaceuticals worth $374,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. Emerald Advisers Inc. PA boosted its position in Reata Pharmaceuticals by 13.2% in the first quarter. Emerald Advisers Inc. PA now owns 370,199 shares of the company’s stock worth $8,385,000 after buying an additional 43,052 shares in the last quarter. Emerald Mutual Fund Advisers Trust boosted its position in Reata Pharmaceuticals by 19.7% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 274,692 shares of the company’s stock worth $6,222,000 after buying an additional 45,133 shares in the last quarter. FMR LLC boosted its position in Reata Pharmaceuticals by 40.6% in the first quarter. FMR LLC now owns 237,606 shares of the company’s stock worth $5,382,000 after buying an additional 68,600 shares in the last quarter. State Street Corp boosted its position in Reata Pharmaceuticals by 5.1% in the fourth quarter. State Street Corp now owns 100,414 shares of the company’s stock worth $2,191,000 after buying an additional 4,879 shares in the last quarter. Finally, Daiwa Securities Group Inc. bought a new position in Reata Pharmaceuticals during the first quarter worth $829,000. Institutional investors and hedge funds own 21.85% of the company’s stock.

Reata Pharmaceuticals, Inc. (NASDAQ RETA) traded down 0.78% during trading on Tuesday, reaching $28.05. The company’s stock had a trading volume of 11,159 shares. The firm’s market capitalization is $732.19 million. Reata Pharmaceuticals, Inc. has a 52-week low of $18.08 and a 52-week high of $41.60. The stock’s 50-day moving average is $29.92 and its 200 day moving average is $26.33.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/29/tiaa-cref-investment-management-llc-cuts-stake-in-reata-pharmaceuticals-inc-reta.html.

RETA has been the subject of a number of analyst reports. Citigroup Inc. restated a “buy” rating and issued a $78.00 price target (down previously from $87.00) on shares of Reata Pharmaceuticals in a report on Wednesday, August 23rd. Piper Jaffray Companies restated an “overweight” rating and issued a $53.00 price target (up previously from $48.00) on shares of Reata Pharmaceuticals in a report on Monday, June 5th. ValuEngine upgraded Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 27th. Zacks Investment Research cut Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 13th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $50.00 price target (up previously from $38.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. Reata Pharmaceuticals has an average rating of “Buy” and an average price target of $54.33.

In other Reata Pharmaceuticals news, major shareholder A/S Novo sold 222,503 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $25.71, for a total value of $5,720,552.13. Following the sale, the insider now owns 746,297 shares in the company, valued at $19,187,295.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James Edward Bass acquired 8,064 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was acquired at an average price of $31.00 per share, for a total transaction of $249,984.00. Following the purchase, the director now directly owns 67,411 shares of the company’s stock, valued at $2,089,741. The disclosure for this purchase can be found here. Insiders sold 471,886 shares of company stock worth $12,541,056 in the last 90 days. Corporate insiders own 62.40% of the company’s stock.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Want to see what other hedge funds are holding RETA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reata Pharmaceuticals, Inc. (NASDAQ:RETA).

Institutional Ownership by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Stock Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.